2-(3-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)phenyl)-2-methyl-propionic acid | 885066-67-1

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(3-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)phenyl)-2-methyl-propionic acid
• 英文别名: Pgd2-IN-1；2-[3-[6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropanoic acid
• CAS: 885066-67-1
• 化学式: C₂₃H₂₃Cl₂N₃O₃
• 分子量: 460.36
• InChiKey: FJKKCRCBBAXLQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  682.1±65.0 °C(Predicted)
• 密度：
  1.326±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥25mg/mL（54.31mM）

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  84.3
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 储存条件：
  |-20℃|

制备方法与用途

生物活性

PGD2-IN-1 是DP受体拮抗剂，来自专利WO 2006044732 A2，化合物实例15 (d)，其IC50值为0.3 nM。

靶点

IC50: 0.3 nM

体外研究

前列腺素D2（PGD2）是一种主要的炎症介质，在哮喘和过敏性鼻炎中发挥作用。它主要通过过敏原刺激肥大细胞脱颗粒后产生。使用DP受体拮抗剂阻断PGD2已被证明在多种物种中有效缓解过敏性鼻炎的症状，并且特别能够抑制抗原引起的鼻塞。

反应信息

• 作为反应物：
  描述：

  2-(3-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)phenyl)-2-methyl-propionic acid 在 磷酸 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以95.6%的产率得到2-(3-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxypyrimidin-4-yl)phenyl)-2-methylpropionic acid, phosphate salt
  参考文献：
  名称：

  [EN] A NEW PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL}-PHENYL)- 2-METHYLPROPIONIC ACID
  [FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE L'ACIDE 2-(3-{6-[2-(2,4-DICHLOROPHÉNYL)-ÉTHYLAMINO]-2-MÉTHOXYPYRIMIDIN-4-YL}-PHÉNYL)- 2-MÉTHYLPROPIONIQUE

  摘要：

  公开号：

  WO2009006086A3
• 作为产物：
  描述：

  2-(3-溴苯基)-2-甲基丙酸 在 四(三苯基膦)钯 叔丁基锂 、 sodium carbonate 作用下， 以 乙醚 、 乙腈 、 正戊烷 为溶剂， 反应 16.0h， 生成 2-(3-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)phenyl)-2-methyl-propionic acid
  参考文献：
  名称：

  WO2007/121280

  摘要：

  公开号：

文献信息

• DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST
  申请人：LANGEVIN Beverly

  公开号：US20080194600A1

  公开（公告）日：2008-08-14

  The present invention is directed to dihydrogen phosphate salt 2-(3-6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like, by administering to said patient a pharmaceutically effective amount of the compound of Formula (III).

  本发明涉及公式（III）的二氢磷酸盐2-（3-6-[2-（2,4-二氯苯基）-乙基氨基]-2-甲氧基嘧啶-4-基}-苯基）-2-甲基丙酸，以及包含该化合物的药物组合物，其中药物组合物包含药学上有效量的化合物（III）和药学上可接受的载体；以及通过向患有PGD2介导的疾病的患者（包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞增多症，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管痉挛，支气管炎，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），由于瘙痒行为（如抓挠和敲打）而次生产生的疾病（如白内障，视网膜脱离，炎症，感染和睡眠障碍），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等）中，向该患者投予药学上有效量的化合物（III）的方法。
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Lim Sungtaek

  公开号：US20070244131A1

  公开（公告）日：2007-10-18

  The present invention is directed to a compound of Formula (I) wherein Cy 1 , Cy 2 , L 1 , L 2 , and R 1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式（I）的化合物，其中Cy1，Cy2，L1，L2和R1如本文所定义，一种制药组合物，包括一种或多种按照式（I）的化合物的药物有效量与药学可接受载体的混合物，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞病，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），疾病（如白内障，视网膜脱落，炎症，感染和睡眠障碍），这些疾病是由于伴随瘙痒的行为（如搔抓和敲打）而次生产生的，炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向该患者注射按照式（I）的化合物的药物有效量。
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：STEFANY David

  公开号：US20090036469A1

  公开（公告）日：2009-02-05

  The present invention is directed to a compound of formula (I), wherein R 1 and R 2 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder by administering to said patient a pharmaceutically effective amount of a compound of the invention.

  本发明涉及一种式（I）的化合物，其中R1和R2如本文所定义，以及一种制药组合物，该组合物包含一种或多种本发明化合物的药效量与药物可接受载体混合，并通过向患有PGD2介导的疾病的患者投与本发明化合物的药效量来治疗患者的方法。
• NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID
  申请人：HANNA Reda G.

  公开号：US20100184979A1

  公开（公告）日：2010-07-22

  This invention is directed to a process for preparing 2-(3-6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid.

  本发明涉及一种制备2-(3-6-[2-(2,4-二氯苯基)-乙基氨基]-2-甲氧基嘧啶-4-基}-苯基)-2-甲基-丙酸的方法。
• 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
  申请人：Aventis Pharmaceuticals, Inc.

  公开号：US07517889B2

  公开（公告）日：2009-04-14

  The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式(I)化合物，其中Cy1、Cy2、L1、L2和R1的定义如本文所述，一种制药组合物，包括一种或多种式(I)化合物的药物有效量与药物可接受载体混合，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身肥大细胞病、伴随全身肥大细胞激活的疾病、过敏性休克、支气管收缩、支气管炎、荨麻疹、湿疹、伴随瘙痒的疾病（如特应性皮炎和荨麻疹）、由于瘙痒行为（如搔抓和打击）引起的疾病（如白内障、视网膜脱落、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等，通过向该患者投予符合式(I)的化合物的药物有效量实施。